Back to News & Events

Alexandria Center for Life Science

Location


450 East 29th Street
New York
NY
10016

Next Event

No upcoming events

Loading Map….

Upcoming Events

  • No events in this location
  • Related Stories

    WP_Query Object
    (
        [query] => Array
            (
                [post_type] => post
                [posts_per_page] => 3
                [post_status] => publish
                [orderby] => rand
            )
    
        [query_vars] => Array
            (
                [post_type] => post
                [posts_per_page] => 3
                [post_status] => publish
                [orderby] => rand
                [error] => 
                [m] => 
                [p] => 0
                [post_parent] => 
                [subpost] => 
                [subpost_id] => 
                [attachment] => 
                [attachment_id] => 0
                [name] => 
                [pagename] => 
                [page_id] => 0
                [second] => 
                [minute] => 
                [hour] => 
                [day] => 0
                [monthnum] => 0
                [year] => 0
                [w] => 0
                [category_name] => 
                [tag] => 
                [cat] => 
                [tag_id] => 
                [author] => 
                [author_name] => 
                [feed] => 
                [tb] => 
                [paged] => 0
                [meta_key] => 
                [meta_value] => 
                [preview] => 
                [s] => 
                [sentence] => 
                [title] => 
                [fields] => 
                [menu_order] => 
                [embed] => 
                [category__in] => Array
                    (
                    )
    
                [category__not_in] => Array
                    (
                    )
    
                [category__and] => Array
                    (
                    )
    
                [post__in] => Array
                    (
                    )
    
                [post__not_in] => Array
                    (
                    )
    
                [post_name__in] => Array
                    (
                    )
    
                [tag__in] => Array
                    (
                    )
    
                [tag__not_in] => Array
                    (
                    )
    
                [tag__and] => Array
                    (
                    )
    
                [tag_slug__in] => Array
                    (
                    )
    
                [tag_slug__and] => Array
                    (
                    )
    
                [post_parent__in] => Array
                    (
                    )
    
                [post_parent__not_in] => Array
                    (
                    )
    
                [author__in] => Array
                    (
                    )
    
                [author__not_in] => Array
                    (
                    )
    
                [search_columns] => Array
                    (
                    )
    
                [ignore_sticky_posts] => 
                [suppress_filters] => 
                [cache_results] => 1
                [update_post_term_cache] => 1
                [update_menu_item_cache] => 
                [lazy_load_term_meta] => 1
                [update_post_meta_cache] => 1
                [nopaging] => 
                [comments_per_page] => 50
                [no_found_rows] => 
                [order] => 
            )
    
        [tax_query] => WP_Tax_Query Object
            (
                [queries] => Array
                    (
                    )
    
                [relation] => AND
                [table_aliases:protected] => Array
                    (
                    )
    
                [queried_terms] => Array
                    (
                    )
    
                [primary_table] => wp_posts
                [primary_id_column] => ID
            )
    
        [meta_query] => WP_Meta_Query Object
            (
                [queries] => Array
                    (
                    )
    
                [relation] => 
                [meta_table] => 
                [meta_id_column] => 
                [primary_table] => 
                [primary_id_column] => 
                [table_aliases:protected] => Array
                    (
                    )
    
                [clauses:protected] => Array
                    (
                    )
    
                [has_or_relation:protected] => 
            )
    
        [date_query] => 
        [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
    					 FROM wp_posts 
    					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
    					 
    					 ORDER BY RAND()
    					 LIMIT 0, 3
        [posts] => Array
            (
                [0] => WP_Post Object
                    (
                        [ID] => 4488
                        [post_author] => 4
                        [post_date] => 2024-10-24 10:45:00
                        [post_date_gmt] => 2024-10-24 14:45:00
                        [post_content] => 
    

    Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

    The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

    New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

    A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

    New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

    Read the press release of Governor Hochul's announcement here:
    https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

    [post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2939 [post_author] => 3 [post_date] => 2018-02-01 16:55:18 [post_date_gmt] => 2018-02-01 16:55:18 [post_content] =>

    Chronus Pharmaceuticals has announced that it has received a $299,172 Phase I Small Business Technology Transfer (STTR) award in partnership with the Department of Chemistry at Stony Brook University.

    Funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) will be used to establish feasibility of an antibody diagnostic for detecting childhood tuberculosis. The research will be lead by LIBH Researcher Nicole S. Sampson, PhD in the Department of Chemistry, who will serve as principle investigator on the award and work in close collaboration with Chronus Pharmaceuticals. [post_title] => Chronus Pharmaceuticals Receives Phase I STTR [post_excerpt] => Chronus Pharmaceuticals has received a $299,172 Phase I Small Business Technology Transfer (STTR) award in partnership with the Department of Chemistry at Stony Brook University. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => chronus-pharmaceuticals-receives-phase-i-sttr [to_ping] => [pinged] => [post_modified] => 2018-02-01 16:55:18 [post_modified_gmt] => 2018-02-01 16:55:18 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2939 [menu_order] => 125 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3908 [post_author] => 1 [post_date] => 2022-06-13 13:15:29 [post_date_gmt] => 2022-06-13 13:15:29 [post_content] =>


    The Center for Biotechnology will be co hosting a series of 6- 90 minute panel discussions with industry and government partners, focused on providing guidance and insight into how innovators can take their solution from the benchtop to the Biomedical Advanced Research & Development Authority (BARDA).

    Each event will have its own specific focus, while contributing to a sequential flow for the series. Experts with specific backgrounds will provide an overview of key resources available to innovators to help fund and advance their solution from early through late stages of development, as well as provide guidance on how to navigate the funding opportunities within BARDA and BARDA DRIVe.

    Session dates: June 14, 17, 21, 24, 28 and July 1st. 12:00om - 1:#0pm EST. Learn more and register: 
    https://lnkd.in/gYnTAgDh

    This program is a collaborative effort between incubators and accelerators who are partnered with them through their Division of Research, Innovation & Ventures (DRIVe).

    [post_title] => Bench to BARDA Start Up Series (Virtual) [post_excerpt] => A virtual series providing insight into how innovators can take their solution from the benchtop to the Biomedical Advanced Research & Development Authority (BARDA). [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bench-to-barda-start-up-series-virtual [to_ping] => [pinged] => [post_modified] => 2022-09-12 15:45:01 [post_modified_gmt] => 2022-09-12 15:45:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3908 [menu_order] => 24 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2836 [post_author] => 1 [post_date] => 2017-09-29 14:45:07 [post_date_gmt] => 2017-09-29 14:45:07 [post_content] => Traverse Biosciences, lead by CFB BioEntrepreneur-in-Residence (B-EIR) Joseph Scaduto, has announced that the National Institutes of Health (NIH) has accepted the company into its competitive Commercialization Accelerator Program (CAP). Hosted in partnership with the Larta Institute, NIH CAP is a 9-month program that is well-regarded for its combination of deep domain expertise and access to industry connections, which have resulted in measurable gains and accomplishments by participating companies. It is open only to NIH SBIR/STTR Phase II awardees, with only 80 slots available each year. The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them. Last year, Traverse Biosciences announced that it had received a $1.3M Phase II Small Business Technology Transfer (STTR) award in partnership with the School of Dental Medicine at Stony Brook University. Read the full Traverse Biosciences announcement here. [post_title] => Traverse Biosciences Accepted into NIH Commercialization Accelerator Program (CAP) [post_excerpt] => CFB BEIR-led Traverse Biosciences will enter the exclusive 9-month program which enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => traverse-biosciences-accepted-into-nih-commercialization-accelerator-program-cap [to_ping] => [pinged] => [post_modified] => 2018-01-23 14:39:02 [post_modified_gmt] => 2018-01-23 14:39:02 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2836 [menu_order] => 137 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

    Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

    The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

    New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

    A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

    New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

    Read the press release of Governor Hochul's announcement here:
    https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

    [post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 259 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

    Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

    More Information

    Chronus Pharmaceuticals Receives Phase I STTR

    More Information

    Bench to BARDA Start Up Series (Virtual)

    More Information

    Traverse Biosciences Accepted into NIH Commercialization Accelerator Program (CAP)

    More Information